Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of lunsekimig (SAR443765) in high-risk asthma patients not eligible for biologics
jRCT2031250380Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Lunsekimig with Placebo (2 arms). Primary endpoint: Annualized rate of asthma exacerbation events. Started Dec 2025; status: active, not recruiting.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031250380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250380.